Hey batman , looking at it from the point of view of a chartist...

Hey batman , looking at it from the point of view of a chartist who knows nothing of the product , I would have to say you are correct . Biotech investing is a little different and you not only need to know your own product , but you also need to know the other emerging products in the field . At the end of the day with a biotech it is the science that counts . There is no way Solbec will have the resources to bring this to market in their present form . Unless of course (and it is a possibility)the phase 2 results are so compelling that it is given accelerated approval and rushed to market . Otherwise I would hope they are able to complete phase 2 before signing any license agreement on the technology , which has been their stated aim all along .
The fact that the shares did not move up on the back of the phase 1 trial results is also true . I guess most people dont understand how outstanding those results are . The value is there IMO and from here its just a case of timing .